Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Average Rating of “Hold” from Analysts

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) have been assigned a consensus rating of “Hold” from the five analysts that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $3.33.

A number of brokerages recently weighed in on SYRS. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Piper Sandler restated an “overweight” rating and set a $5.00 price target (down previously from $13.00) on shares of Syros Pharmaceuticals in a report on Tuesday, August 13th. Finally, StockNews.com assumed coverage on Syros Pharmaceuticals in a report on Saturday. They set a “sell” rating on the stock.

Insider Buying and Selling

In other Syros Pharmaceuticals news, CEO Conley Chee bought 50,000 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was acquired at an average cost of $1.51 per share, for a total transaction of $75,500.00. Following the completion of the transaction, the chief executive officer now owns 72,504 shares in the company, valued at $109,481.04. This trade represents a 222.18 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nancy A. Simonian sold 134,713 shares of Syros Pharmaceuticals stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the sale, the director now owns 41,070 shares of the company’s stock, valued at $11,088.90. The trade was a 76.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders purchased 130,707 shares of company stock worth $206,491. Corporate insiders own 12.26% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SYRS. Vanguard Group Inc. lifted its stake in Syros Pharmaceuticals by 21.3% in the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after acquiring an additional 163,234 shares during the period. Certuity LLC acquired a new position in shares of Syros Pharmaceuticals during the second quarter worth $109,000. Acadian Asset Management LLC increased its position in Syros Pharmaceuticals by 101.5% during the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after buying an additional 17,416 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Syros Pharmaceuticals during the 3rd quarter worth approximately $34,000. Institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Price Performance

NASDAQ:SYRS opened at $0.24 on Friday. The stock has a market cap of $6.44 million, a PE ratio of -0.08 and a beta of 1.33. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97. The business’s 50-day simple moving average is $1.51 and its two-hundred day simple moving average is $3.22. Syros Pharmaceuticals has a 52 week low of $0.18 and a 52 week high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same period in the previous year, the firm earned ($1.35) earnings per share. As a group, analysts forecast that Syros Pharmaceuticals will post -2.94 EPS for the current fiscal year.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.